Oldenburg, Bas

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

Gadaleta, R. M., van Erpecum, K. J., Oldenburg, B., Willemsen, E. C. L., Renooij, W., Murzilli, S., Klomp, L. W. J., Siersema, P. D., Schipper, M. E. I., Danese, S., et al. (2011) · Gut

Inflammatory Bowel DiseaseGut microbiota and health

Cited by 870

Prevention of exercise-induced muscle membrane damage by oestradiol

Bär, P. R., Amelink, G. J., Oldenburg, B., & Blankenstein, M. A. (1988) · Life Sciences

Exercise and Physiological ResponsesMuscle and Compartmental Disorders

Cited by 133

PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation

Petrelli, A., Mijnheer, G., van Konijnenburg, D. P. H., van der Wal, M. M., Giovannone, B., Mocholi, E., Vazirpanah, N., Broen, J. C., Hijnen, D., Oldenburg, B., et al. (2018) · Journal of Clinical Investigation

T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Cited by 126

Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease

Nijmeijer, R. M., Gadaleta, R. M., van Mil, S. W. C., van Bodegraven, A. A., Crusius, J. B. A., Dijkstra, G., Hommes, D. W., de Jong, D. J., Stokkers, P. C. F., Verspaget, H. W., et al. (2011) · PLoS ONE

Inflammatory Bowel DiseaseGut microbiota and health

Cited by 119

High risk of advanced colorectal neoplasia in patients with primary sclerosing cholangitis associated with inflammatory bowel disease

Shah, S. C., ten Hove, J. R., Castaneda, D., Palmela, C., Mooiweer, E., Colombel, J.-F., Harpaz, N., Ullman, T. A., van Bodegraven, A. A., Jansen, J. M., et al. (2018) · Clinical Gastroenterology and Hepatology

Colorectal Cancer Screening and DetectionInflammatory Bowel Disease

Cited by 109